Purpose of reviewBreast cancer is a heterogeneous disease, including different subtypes with their own biology, prognosis, clinical characteristics and treatment. To date, traditional clinical and pathological determinants remain the main factors guiding treatment decision-making; however, the development of multigene assays improved the ability to predict the risk of recurrence in patients with early-stage breast cancer. These tools underwent an extensive independent validation and have already been partly incorporated into clinical practice.Recent findingsThe current article summarizes current evidence for the use of the different genomic assays in clinical practice, their characteristics and validation studies. A few studies comparing available genomic assays revealed that they provide different information with a modest correlation and that they are not interchangeable; other trials are currently ongoing in this setting.SummaryVariability across different gene signatures may be a challenge for the optimal management of the individual patient, hence each assay should be used for the clinical setting in which it has been validated.
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer / C. Criscitiello, G. Viale, G. Curigliano. - In: CURRENT OPINION IN ONCOLOGY. - ISSN 1040-8746. - 31:6(2019 Nov), pp. 472-479. [10.1097/CCO.0000000000000570]
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer
C. Criscitiello
Primo
;G. VialePenultimo
;G. CuriglianoUltimo
Conceptualization
2019
Abstract
Purpose of reviewBreast cancer is a heterogeneous disease, including different subtypes with their own biology, prognosis, clinical characteristics and treatment. To date, traditional clinical and pathological determinants remain the main factors guiding treatment decision-making; however, the development of multigene assays improved the ability to predict the risk of recurrence in patients with early-stage breast cancer. These tools underwent an extensive independent validation and have already been partly incorporated into clinical practice.Recent findingsThe current article summarizes current evidence for the use of the different genomic assays in clinical practice, their characteristics and validation studies. A few studies comparing available genomic assays revealed that they provide different information with a modest correlation and that they are not interchangeable; other trials are currently ongoing in this setting.SummaryVariability across different gene signatures may be a challenge for the optimal management of the individual patient, hence each assay should be used for the clinical setting in which it has been validated.File | Dimensione | Formato | |
---|---|---|---|
Harmonizing_gene_signatures_to_predict_benefit.3.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
220.85 kB
Formato
Adobe PDF
|
220.85 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.